Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today increasing demand from ...
EQS-News: Mynaric AG / Key word (s): Miscellaneous Mynaric Announces Receipt of Deficiency Letter from Nasdaq 08.10.2024 / 12:00 CET/CEST The issuer is solely responsible for the content of this ...